

February 21, 2019

CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28

NEWARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, February 28, 2019 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and fiscal year ended December 31, 2018 and to provide a business update.

Conference Call Details

To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13687140. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at <http://ir.cymbabay.com/events>.

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay's lead development candidate, seladelpar, is a potent, selective and orally active PPAR δ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar (ENHANCE) in patients with PBC. Seladelpar received orphan designation from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for PBC. Seladelpar also received Breakthrough Therapy Designation from the FDA and Priority Medicine status from the EMA for PBC. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar for patients with NASH.

For additional information about CymaBay visit www.cymbabay.com.

Contact:

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com



Source: CymaBay Therapeutics, Inc.